Supplementary

Table S1 Genetic abnormalities and background of patients with TETs harboring *GTF2I*-mutation

Case	Mutation	Age	Sex	WHO histologic classification	Masaoka-Koga staging	Frequency (coverage)	Complications
Case 1	*GTF2I* L424H	71	F	Type A, thymoma	I	42.32% (C=943, T=692)	None
Case 2	HRAS Q61R	55	F	Type AB, thymoma	I	10.61% (T=1786, C=212)	Anti Ach-receptor antibody (+)
	GTF2I L424H					11.34% (T=1009, A=129)	Myasthenia gravis (–)
Case 3	*GTF2I* L424H	63	M	Type AB, thymoma	I	11.79% (C=875, T=117)	Agranulocytosis
Case 4	*GTF2I* L424H	50	F	Type AB, thymoma	I	34.53% (C=1149, T=606)	None
Case 5	*HRAS* G13R	80	M	Type AB, thymoma	IIA	14.84% (C=465, G=81)	None
	GTF2I L424H					13.32% (T=657, A=101)	
Case 6	*GTF2I* L424H	79	F	Type AB, thymoma	IIB	12.11% (C=820, T=113)	None
Case 7	*GTF2I* L424H	68	M	Type AB, thymoma	IIB	32.62% (C=475, T=230)	None
Case 8	*GTF2I* L424H	82	F	Type AB, thymoma	III	38.55% (C=663, T=416)	None
Case 13	*NRAS* Q61K	74	F	Type B1, thymoma	IIB	40.56% (TTG=400, TTT=275)	None
	GTF2I L424H					36.48% (T=383, A=220)	
Case 14	*GTF2I* L424H	64	F	Type B1, thymoma	IIB	5.09% (C=1007, T=54)	Anti Ach-receptor antibody (+)
							Myasthenia gravis (-)
Case 15	*GTF2I* L424H	49	F	Type B1, thymoma	IIB	6.21% (C=1374, T=91)	None
Case 17	*GTF2I* L424H	83	F	Type B2, thymoma	I	37.72% (C=938, T=568)	Anti Ach-receptor antibody (+)
							Myasthenia gravis (-)
Case 30	*ASXL1* R693Ter	76	M	Thymic carcinoma	III	34.52% (C=203, T=107)	None

TETs, thymic epithelial tumors; WHO, World Health Organization; Ach, acetylcholine; F, female; M, male.

https://dx.doi.org/10.21037/tlcr-22-794



Figure S1 Representative results of Sanger sequence of *GTF2I*-mutation after TA cloning.

https://dx.doi.org/10.21037/tlcr-22-794